A practical reference on TB-500: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-14. Anything still debated is marked as such rather than presented as settled.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
== External links == International HapMap Project Archived 2014-04-16 at the Wayback Machine Delaware Valley Personalized Medicine Project Uses SNPs to help make medicine personal Genotyping by Oligonucleotide Ligation Assay (OLA) Why SNP test your mice?
In the above example, the combination of whole rice and canned chickpeas has no limiting amino acids. This means that consuming only rice and chickpeas, in these specific quantities of 306 g/day and 261 g/day respectively, for long periods of time, would easily combine to create complete protein, as it would not result in any of the essential amino acid deficiency. As the data of the example show, all essential amino acids are found in a specific plant. However, one or more of them may be limiting. For this reason, vegan and vegetarian diets need to be varied in terms of plants consumed.
Hyphenated techniques LC–MS (liquid chromatography–mass spectrometry) GC–MS (gas chromatography–mass spectrometry) LC–DAD (liquid chromatography–diode array detection) CE–MS (capillary electrophoresis–mass spectrometry) Chromatographic methods HPLC (high performance liquid chromatography) GC (gas chromatography) UPLC (ultra performance liquid chromatography) Supercritical fluid chromatography Electrophoresis Preparative native polyacrylamide gel electrophoresis Ligand binding assays Dual polarisation interferometry ELISA (Enzyme-linked immunosorbent assay) MIA (magnetic immunoassay) RIA (radioimmunoassay) Mass spectrometry Nuclear magnetic resonance The most frequently used techniques are: liquid chromatography coupled with tandem mass spectrometry (LC–MS/MS) for 'small' molecules and enzyme-linked immunosorbent assay (ELISA) for macromolecules.
Sources: en.wikipedia.org
The company began as a collaboration between a group of entrepreneurs, the professional artist Joseph Lyons and his brothers in law, Isidore and Montague Gluckstein, as a spin off from the Salmon & Gluckstein tobacco company. In 1894 the company started a teashop in Piccadilly, London, and from 1909 developed this into a chain of teashops which would ultimately number around 200 locations. The company also ran high class restaurants, founding the Trocadero in 1895, and hotels including the Strand Palace, opened in 1909, the Regent Palace, opened in 1915, and the Cumberland Hotel, opened in 1933, all in London. In 1918, to increase sales in northern England, Lyons bought the old established tea company Horniman & Sons. From the 1930s Lyons began to develop a pioneering range of teas, biscuits and cakes that were sold in grocery stores across the world. Lyons was appointed to run the company, and it was named after him. J. Lyons & Co. was a pioneer in introducing computers to business. Between 1951 and 1963, the company manufactured and sold a range of LEO (Lyons Electronic Office) computers.
Despite these conclusions, all researchers observed a degree of managerial activities among the groups they studied. All observed networks and a degree of persistence, and there may be utility in focusing on the identification of organizing roles of people and events rather than the group's structure. There may be three main approaches to understand the organizations in terms of their roles as social systems:
=== Acute exacerbations === Acute exacerbations of IPF (AE-IPF) are defined as an unexplained worsening or development of dyspnea within 30 days with new radiological infiltrates at HRCT abnormality often superimposed on a background consistent with UIP pattern. The yearly incidence of AE-IPF is between 10 and 15% of all patients. The prognosis of AE-IPF is poor, with mortality ranging from 78% to 96%. Other causes of AE-IPF such as pulmonary embolism, congestive heart failure, pneumothorax, or infection need to be excluded. Pulmonary infection have to be ruled out by endotracheal aspirate or BAL. Many patients experiencing acute deterioration require intensive care treatment, particularly when respiratory failure is associated with hemodynamic instability, significant comorbidities or severe hypoxemia. However, mortality during hospitalization is high. Mechanical ventilation should be introduced only after carefully weighing the person's long-term prognosis and, whenever possible, the person's wishes. However, current guidelines discourage the use of mechanical ventilation in patients with respiratory failure secondary to IPF.
Small molecule targets Protein targets Cells and tissues Multiple rounds of selection and counter-selection are performed as part of each Optimer discovery process. Each discovery process can be adapted to include specific target, assay and buffer conditions to improve Optimer selection.
Sources: en.wikipedia.org
Hypoglycemia is most common in those with diabetes treated by insulin, glinides, and sulfonylureas. Hypoglycemia is rare in those without diabetes, because there are many regulatory mechanisms in place to appropriately balance glucose, insulin, and glucagon.
=== Musculoskeletal system === Estrogens increase muscle mass and strength, as well as the speed of muscle regeneration. They protect against damage to muscles and increase their sensitivity to exercise. In mice, estrogen supplementation has been shown to restore the proportion of type IIX muscle fibers to over 40% following an ovariectomy. Estrogens promote stronger collagen synthesis, increasing the collagen content of connective tissues, tendons, and ligaments. This decreases the stiffness of tendons and ligaments, especially during menstruation. Women have a lower predisposition to muscle strains, but soft ligaments are more prone to injuries. ACL tears are two to eight times more common among women than men. Estrogens are responsible for both the pubertal growth spurt, which causes an acceleration in linear growth, and epiphyseal closure, which limits height and limb length, in both females and males. In addition, estrogens are responsible for bone maturation and maintenance of bone mineral density throughout life. They reduce bone resorption and promote bone formation. Due to hypoestrogenism, the risk of osteoporosis increases during menopause.
==== Phosphodiesterase PDE5 inhibitors ==== Avanafil (Razatus; Spedra; Stendra; TA-1790; Zepeed) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [114] Lodenafil (CRIS-031; Helleva) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [115] Mirodenafil (Aibishi; Bravonto; Mvix; SK-3530) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [116] Sildenafil (Revatio; Revatio IV; UK-92480; Viagra) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [117] Sildenafil chewable tablets (Nurigra) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [118] Sildenafil orally soluble film (sildenafil ODF; SPO-1101; Vultis) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [119] Sildenafil orally soluble film (orodispersible sildenafil; Please; sildenafil oral dissolving film; sildenafil orally-disintegrating film; sildenafil OSF) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [120] Sildenafil oral spray (ASP-001; ASP-002; Bandol; Hezkue) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [121] Sildenafil oro-dispersible tablets (Erecta; FACSID-50) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [122] Simmerafil (Onvita; Onweida; semenafil; TPN-171; TPN-171-H) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [123] Tadalafil (Adcirca; Cialis; GF-196960; IC-351; LY-450190; Zalutia) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [124] Tadalafil oral disintegrating film (SPO-1102; Vulteum; tadalafil ODF) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [125] Tadalafil oral film (OGOOD) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [126] Udenafil (DA-8159; Jurvigo; ME-3113; MZ101; Udzire; WC-3043; WC-3055; Zydena) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [127] Vardenafil (BAY-389456; Levitra; Nuviva; Staxyn; vardenafil ODT; vardenafil orodispersible tablet; Vivanza) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [128]
=== By affected component === Humoral immune deficiency (including B cell deficiency or dysfunction), with signs or symptoms depending on the cause, but generally include signs of hypogammaglobulinemia (decrease of one or more types of antibodies) with presentations including repeated mild respiratory infections, and/or agammaglobulinemia (lack of all or most antibody production) which results in frequent severe infections and is often fatal. T cell deficiency, often causes secondary disorders such as acquired immune deficiency syndrome (AIDS). Granulocyte deficiency, including decreased numbers of granulocytes (called as granulocytopenia or, if absent, agranulocytosis) such as of neutrophil granulocytes (termed neutropenia). Granulocyte deficiencies also include decreased function of individual granulocytes, such as in chronic granulomatous disease. Asplenia, where there is no function of the spleen Complement deficiency is where the function of the complement system is deficient In reality, immunodeficiency often affects multiple components, with notable examples including severe combined immunodeficiency (primary) and acquired immune deficiency syndrome (secondary).
Usually made for promotional purposes, it is closer to an advertisement than a classic documentary. Modern lightweight digital video cameras and computer-based editing have greatly aided documentary makers, as has the dramatic drop in equipment prices. The first film to take full advantage of this change was Martin Kunert and Eric Manes' Voices of Iraq, where 150 DV cameras were sent to Iraq during the war and passed out to Iraqis to record themselves.
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.